NSDHL

Across TCGA pan-cancer cohorts, NSDHL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NSDHL data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher NSDHL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NSDHL expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

OV, PDAC, and LUAD are the cancer types where NSDHL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.536	0.942	.001	24	view →
PDAC	OS	Median	All	0.447	0.692	.004	21	view →
LUAD	DFS	Quartile	All	0.641	0.891	.009	8	view →
HNSC	DFS	Quartile	II,III,IV	0.813	0.527	.012	5	view →
CCRCC	DFS	Tertile	III,IV	0.974	0.703	.029	3	view →
LSCC	DFS	Quartile	All	0.606	1.000	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NSDHL–OV (DFS)

Open the OV breakdown →